Industry Experts

Zheng Meng is Senior Director of Global CMC Development at Ultragenyx, where he leads a cross-functional CMC team for a clinical-stage AAV gene therapy program and oversees potency assay development for both biologics and gene therapy platforms. Prior to joining Ultragenyx, he held roles at Novavax, Biogen, and Five Prime Therapeutics (acquired by Amgen), contributing to early- and late-stage development across diverse modalities, including monoclonal antibodies, enzymes, recombinant vaccines, and mRNA-LNP—targeting rare genetic diseases, infectious diseases, and immuno-oncology.

Zheng earned his B.S. in Biology from Tsinghua University and his Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham (UAB), followed by postdoctoral research at Caltech.